A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy
Clinical trial NCT04749394 · UNKNOWN
Trial details
- NCT number
- NCT04749394
- Sponsor
- Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-17
- Primary completion
- 2025-01-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.